Lucid Diagnostics Q1 2026 earnings snapshot

Lucid Diagnostics (LUCD) has just posted its Q1 2026 numbers with revenue of about US$1.3 million, a basic EPS loss of US$0.17, and a net loss of roughly US$23.6 million, setting a cautious tone around profitability. Over the past year, the company has seen quarterly revenue move from US$0.8 million in Q1 2025 to a range of roughly US$1.2 million to US$1.5 million more recently, while quarterly EPS losses shifted between about US$0.52 and US$0.08, before widening again in Q1 2026. For investors, the headline is that top line is still modest while losses and margin pressure remain central to the story.

See our full analysis for Lucid Diagnostics.

With the latest figures on the table, the next step is to see how these results line up with the prevailing growth focused and risk focused narratives around Lucid Diagnostics.

Losses widen again to US$23.6 million

• Lucid reported a net loss of US$23.6 million in Q1 2026, compared with US$16.3 million in Q4 2025 and US$10.4 million in Q3 2025, while trailing 12 month losses were US$58.2 million.
• Bears often point to this pattern of losses as a warning, arguing that ongoing high cash burn and delayed reimbursement could keep Lucid unprofitable for longer. However, the numbers show a more mixed picture:
  • On one hand, quarterly net losses have swung from US$36.0 million in Q1 2025 down to US$7.9 million in Q2 2025, then back up to US$23.6 million in Q1 2026, which fits the cautious view that earnings are still volatile.
  • On the other hand, trailing 12 month losses of US$58.2 million are smaller than the US$70.9 million loss recorded on a trailing basis at Q1 2025, which softens the most extreme bearish claim of steadily worsening results even though the company remains clearly unprofitable.

Stay on top of how skeptics interpret this loss pattern and what they think it means for Lucid's runway and capital needs. 🐻 Lucid Diagnostics Bear Case

Revenue base still small at US$5.1 million LTM

• Over the last 12 months to Q1 2026, Lucid generated total revenue of US$5.1 million, up from US$4.7 million at Q4 2025 and US$4.2 million at Q1 2025, with recent quarterly revenue moving between US$0.8 million and US$1.5 million.
• Supporters lean on high forecast revenue growth to justify patience, and the current scale partly lines up with that bullish angle while also testing it:
  • Consensus narrative points to forecast revenue growth of about 38.7% per year, yet the actual trailing 12 month revenue of US$5.1 million shows the business is still very early stage and any high growth forecast starts from a modest base.
  • The bullish case that expanded insurance coverage could accelerate test adoption sits next to a reality where quarterly revenue has only shifted from US$0.8 million in Q1 2025 to a band of around US$1.2 million to US$1.5 million, so investors need to judge how quickly that forecast ramp might show up in reported numbers.

See how bullish investors link these early revenue figures to their growth narrative and what would need to change in future reports. 🐂 Lucid Diagnostics Bull Case

High P/S multiple and dilution raise the bar

• The stock trades on a P/S of 37.9x, far above the US Medical Equipment industry at 2.7x and peers at 9.1x, while shareholders have also faced substantial dilution over the past year.
• Consensus narrative flags this valuation as demanding, and the current earnings profile reinforces how much Lucid has to deliver to support it:
  • With trailing 12 month revenue of US$5.1 million and losses of US$58.2 million, a 37.9x P/S multiple and ongoing dilution mean each extra dollar of revenue and any progress toward profitability carry extra weight for per share outcomes.
  • Analysts point to a US$4.10 price target alongside a current share price of US$1.02, so anyone using that gap as a reference still has to weigh it against the combination of forecast unprofitability over the next three years and the high multiple relative to industry and peers.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Lucid Diagnostics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After weighing both the cautious and optimistic angles in this update, promptly review the underlying numbers and form your own view using 1 key reward and 2 important warning signs.

See What Else Is Out There

Lucid’s widening losses, small revenue base, high P/S multiple, and ongoing dilution create a demanding setup that may not suit every risk profile.

If that mix of volatility and funding risk feels uncomfortable, quickly compare it with companies focused on resilience and capital preservation using the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.